Thompson Davis & Co’s Pacific Biosciences PACB Stock Holding History

Thompson Davis & Co’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-500	Closed	-$3K	–	1214
2015 Q2	$3K	Hold	500	–	–	﹤0.01%	1021
2015 Q1	$3K	Hold	500	–	–	﹤0.01%	1023
2014 Q4	$4K	Hold	500	–	–	﹤0.01%	994
2014 Q3	$2K	Buy	+500	New	+$2.61K	﹤0.01%	1056

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Thompson Davis & Co's PACB Position: Q3 2015 in Review

Thompson Davis & Co sold out of Pacific Biosciences (PACB) in Q3 2015, closing a stake of 500 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in PACB in Q3 2014 and held it in 4 quarters. The position peaked at $4K in Q4 2014. 90 funds tracked by Wall St. Rank hold PACB as of Q3 2015.

Thompson Davis & Co reported no remaining Pacific Biosciences position as of Q3 2015 after selling out during the quarter.
Thompson Davis & Co sold 500 Pacific Biosciences shares in Q3 2015, an estimated $3K.
Thompson Davis & Co first reported a position in Pacific Biosciences in Q3 2014 and held it in 4 quarters.
Thompson Davis & Co's Pacific Biosciences position peaked at $4K in Q4 2014.
90 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2015.

Based on Thompson Davis & Co's 13F filing for Q3 2015, filed 30 Oct 2015.